Search

Displaying results 4891 - 4900 of 9724 in total
  1. Drug

    Repaglinide

    go.drugbank.com/drugs/DB00912
    ApprovedInvestigational

    Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. … Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine.

  2. Drug

    Buprenorphine

    go.drugbank.com/drugs/DB00921
    ApprovedIllicitInvestigationalVet approved

    Clinically, this results in a slow onset of action and a clinical phenomenon known as the "ceiling effect" where once a certain dose is reached, buprenorphine's effects plateau. … Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain.

    Products: BUPRENORPHIN AL 5UG/H, BUPRENORPHIN AL 10UG/H
  3. Drug

    Cyclobenzaprine

    go.drugbank.com/drugs/DB00924
    ApprovedInvestigational

    Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977. … [A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.

    Synonyms: (3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-amine, N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamine
  4. Drug

    Phenoxybenzamine

    go.drugbank.com/drugs/DB00925
    ApprovedInvestigational

    It has been used to treat hypertension and as a peripheral vasodilator.

  5. Drug

    Cycrimine

    go.drugbank.com/drugs/DB00942
    Approved

    Cycrimine is a drug used to reduce levels of acetylcholine to return a balance with dopamine in the treatment and management of Parkinson's disease.

  6. Drug

    Zalcitabine

    go.drugbank.com/drugs/DB00943
    ApprovedWithdrawn

    A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. … The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase.

  7. Drug

    Demecarium

    go.drugbank.com/drugs/DB00944
    Approved

    It is a cholinesterase inhibitor or an anticholinesterase. … The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure.

  8. Drug

    Fexofenadine

    go.drugbank.com/drugs/DB00950
    ApprovedInvestigational

    [A1452] Fexofenadine is the major active metabolite of [terfenadine][A1495] and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity.

  9. Drug

    Naratriptan

    go.drugbank.com/drugs/DB00952
    Approved

    Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.

    Categories: Monoamine Oxidase A SubstratesProducts: NARATRIPTAN AL 2.5MG, NARATRIPTAN 1A PHAR 2.5MG
  10. Drug

    Rizatriptan

    go.drugbank.com/drugs/DB00953
    ApprovedInvestigational

    Rizatriptan is a second-generation triptan [A258918] and a selective 5-HT<sub>1B and 5-HT1D</sub> receptor agonist.

    Categories: Monoamine Oxidase A SubstratesProducts: RIZATRIPTAN AL 5MG TABL, RIZATRIPTAN AL 10MG TABL